PRESS-RELEASE filed Aug 20, 2026 at 07:30 ET
Evaxion reported Q2 2026 net loss of $3.7M, in line with expectations and improved from $4.8M a year ago, with cash of $14.0M funding operations into H2 2027. The company highlighted pipeline progress including upcoming ESMO data for EVX-01 and preclinical advances for EVX-04 and EVX-05, but reported zero revenue and a GAAP EPS of -$0.01, which was a 4900% miss vs the -$0.01 consensus estimate due to a rounding artifact on a tiny base. The filing is neutral as the financials were as expected and the EPS miss is mechanical on a pre-revenue biotech with minimal analyst coverage, while pipeline catalysts are forward-looking and uncertain.